Last update 23 Jan 2025

NA-931

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Target
GCGR x GIPR x GLP-1R x IGF-1R
Mechanism
GCGR agonists(Glucagon receptor agonists), GIPR agonists(Gastric inhibitory polypeptide receptor agonists), GLP-1R agonists(Glucagon-like peptide 1 receptor agonists)
+ [1]
Therapeutic Areas
Endocrinology and Metabolic Disease
Active Indication
ObesityDiabetes Mellitus, Type 2
Inactive Indication-
Originator Organization
Biomed SA
Active Organization
Biomed SABiomed Industries, Inc.
Inactive Organization-
Drug Highest PhasePhase 2/3
First Approval Date-
Regulation-
Login to view timeline

Related

3
Clinical Trials associated with NA-931
NCT06732245
/ Not yet recruitingPhase 2
A Randomized, Double-Blind, Placebo-Controlled Multi-Center Study of Oral NA-931, Alone or in Addition to Open Label Subcutaneous Tirzepatide , to Investigate the Efficacy and Safety in Overweight or Obese Men and Women
NCT06564753
/ RecruitingPhase 2
A Phase 2 Randomized, Double-Blind, Placebo-Controlled, 13-week Study of NA-931 for Weight Management in Subjects Who Are Obese or Overweight With at Least One Weight-related Comorbid Condition
NCT06615700
/ CompletedPhase 1
A Randomized, Double-Blind, Placebo-Controlled Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of NA-931 in Overweight/Obese Participants and in Patients With Type 2 Diabetes Mellitus
100 Clinical Results associated with NA-931
Login to view more data
100 Translational Medicine associated with NA-931
Login to view more data
100 Patents (Medical) associated with NA-931
Login to view more data
100 Deals associated with NA-931
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
ObesityPhase 3-
Biomed SA
-
Diabetes Mellitus, Type 2Phase 1
AU
Biomed Industries, Inc.
06 May 2024
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
NCT06615700 (NA-931-050, Company_Website)
ManualManual
Phase 1
Obesity
-
(qlquphagpm) = ixdqbagicw yumvfmalhm (ptcaoqyvmo )
View more
Positive
07 Oct 2024
Placebo
(qlquphagpm) = qjdtvnkswe yumvfmalhm (ptcaoqyvmo )
NA-931 (ADA2024)
Not Applicable
glucose | lipids
-
tayjhicxbe(mhigsghhsz) = gnkxsubuao uxkcshzzgz (bpjcxyjlhc )
Positive
14 Jun 2024
NA-932
tayjhicxbe(mhigsghhsz) = hobdgmxtaf uxkcshzzgz (bpjcxyjlhc )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free